All News
Contraception counselling in #SLE post intervention
- Contraceptive counseling rates improved from 33.9% to 55.7%
- Women over 35 were 4.09 times more likely post-intervention
- Non-Hispanic Black women were less likely than Hispanic women
#ACR24 abst#0184 @RheumNow https://t.co/sOZXnAe4ov
Bella Mehta bella_mehta ( View Tweet)
High serum BAFF as a novel RF for dev't of preeclampsia in pregnant SLE pts?
This study by Dr. C Sims et al showed that SLE pregnancies w/preeclampsia had significantly higher BAFF levels during the 1st trimester, and likely w/ ⬆️dsDNA or ⬇️ complement
@RheumNow #ACR24 abs424 https://t.co/kNzyuT03r2
sheila RHEUMarampa ( View Tweet)
This interesting systematic review showed that the prevalence of ILD was 15% in patients with SLE. This higher than previously reported! #ACR24 @RheumNow https://t.co/O1aZUUL4Ho
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Researchers developed a digital messaging program to reduce fatigue in SLE
- Grounded in social cognitive and self-determination theories
- Reviewed 148 messages, refined based on patient feedback
- High patient ratings, future will see more of these #ACR24 abst#0362 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Ab#0427 #ACR24
HSS: menopause & systemic rheum disease severity
1/3 women report worse disease associated w menopause
Reported more flares, menopausal symptoms
Findings were similar between SLE and RA, but SLE patients were >2x more likely to discuss w their rheum
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
#ACR24 abst#0430
- Analyzed 61 SLE pregnancies
- Higher early gestational Mean Arterial Pressure before 20 Weeks linked to increased preeclampsia risk
- MAP trends at 8-10 and 17-19 weeks showed highest predictive accuracy for risk prediction
@RheumNow https://t.co/37mg0WX43v
Bella Mehta bella_mehta ( View Tweet)
FDA recently approved - fms-like tyrosine kinase 1 (s-Flt1) / placental growth factor (PlGF), for diagnosing preeclampsia.
sFlt1:PlGF≤38 rules out preeclampsia in SLE
sFlt1:PlGF>85 modestly predicts preeclampsia
Proteinuria impacts prediction accuracy #ACR24 abst#0809 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Nationwide US study
-Prevalence of HLH in SLE: 0.13%
-Higher risk in younger, female, and racial minority patients
- Strong association with high mortality #ACR24 abst#0619 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Study on #AI-augmented remote care for SLE:
- Combined biometric, self-reported, and NLP-extracted data
- Moderate to strong correlations with physician global assessment
- Potential to improve remote disease management - but now very accurate for now
#ACR24 abst#0635 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Interim analysis of a Phase 4 study of ARD (RA 25%, SLE 25%) patients shows recombinant herpes zoster vaccine(RZV) good safety profile, with no impact on disease activity (flare rates: 13.6% vs. 12.4%). Immunogenicity: 93% response in ARDs vs. 99% in controls. Rituximab & MMF… https://t.co/U3s48fLduX https://t.co/WTvD5shtXB
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Study on socioeconomic factors in SLE hospitalizations - US wide data
- No insurance & non-metro areas linked to shorter LOS, lower costs, higher mortality
- Higher income & age increase charges
- Targeted interventions needed to improve outcomes
#ACR24 abst#0615 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Study on pregnancy outcome disparities in SLE:
- Analyzed 685 women, 1888 pregnancies
- Pre-SLE state linked to fewer live births, higher preeclampsia risk
- Outcomes worse post-SLE diagnosis
#ACR24 abst#0440 @RheumNow https://t.co/NpEYQZ73uo
Links:
Bella Mehta bella_mehta ( View Tweet)
Briefly highlighting this poster, always looking for a non-Georg Schett CAR-T study to see if their results replicate
All 10 pts in this one had a "complete humoral response," normalizing antibodies & experiencing long term drug-free remission
#ACR24 @RheumNow Abstr#0673 https://t.co/pjOjRnJVhO
Mike Putman EBRheum ( View Tweet)
This poster makes me happy for so many reasons 😆
Aggressive & descriptive title? ☑️
Pretty chloropleth map? ☑️
Dunks on hamfisted EMR tools trying to replace patient-physician interactions? ☑️
@RheumNow #ACR24 Abstr#0668 ThereAreNoShortcuts https://t.co/IXYaHAi15q
Mike Putman EBRheum ( View Tweet)
This is likely an oversimplification, but I've been looking for exactly this diagram
Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition
@EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No?
@rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3
Links:
Mike Putman EBRheum ( View Tweet)
Ok so trivial tweet here but I just love the name of this outcome measure... "LFA-REAL" 😄😆
Serious topic though; PRO's are huge in SLE research!
@RheumNow #ACR24 Abstr#0626 https://t.co/w34zTNjSbH
Mike Putman EBRheum ( View Tweet)
🧬 #SLE patients show major community mobility limits: 50% don't leave their neighborhood weekly without help. Life Space Assessment finds lower mobility vs. other chronic conditions. Better mobility linked to higher SES & lower disease activity. @RheumNow #ACR24 abst#0145 https://t.co/2sfXNlJ9JD
Bella Mehta bella_mehta ( View Tweet)
Shu et al. Rituximab followed by Telitacicept in refractory/severe APS. Significantly fewer new clinical events in Telitacicept group over 24 weeks (1/21 vs. 6/20) @RheumNow #ACR24 Abstr#0129 https://t.co/hjUQkNNk5w https://t.co/QLQbZ3wQx0
Links:
Richard Conway RichardPAConway ( View Tweet)
🔍 Study on lupus & APS highlights key links! APS patients face higher rates of developing SLE, and vice versa. Notable predictors: females, lupus anticoagulant, and specific antibodies. These insights stress the need for vigilant monitoring in both. #ACR24 @RheumNow Abst#0119
Bella Mehta bella_mehta ( View Tweet)
Prevalence of HLH among pts w/SLE: lower than consults would suggest!
Observational study using NIS: 139 cases out of >100k pts w/SLE (0.13%); 6 fold increase in mortality
Fits my priors; HLH is overdiagnosed, but bad when it happens
@RheumNow #ACR24 Abstr#0619 https://t.co/iz3BlUOJb9
Mike Putman EBRheum ( View Tweet)
